Advertisement Of Notice Of Twenty Third Annual General Meeting, E-Voting And Book Closure Information.
Please find attached herewith the copies of the advertisement of Notice of Twenty Third Annual General Meeting, E-voting and Book Closure information published in the English and Gujarati editions of Financial Express on July 17, 2017 for the perusal of your good office. Zydus Wellness AGM cut-off date for voting
Zydus Wellness has informed the exchanges that pursuant to Companies [Management and Administration] Amendment Rules, 2015, the company has fixed August 3 as the cut-off date for determining the... Cut-Off Date For The Annual General Meeting Dated 11Th August, 2017
This is to inform that pursuant to Companies [Management and Administration] Amendment Rules, 2015, the Company has fixed August 3, 2017 as the Cut-Off Date for determining the eligibility of the members entitled to vote by electronic means and at the venue of Twenty Third Annual General Meeting scheduled to be held on Friday, August 11, 2017 at 12:00 noon.... Meeting Of Board Of Directors / Closure Of Trading Window
We hereby inform that the meeting of the Board of Directors of the Company will be held on Thursday, August 10, 2017 to consider, inter alia, to approve the unaudited financial results for the quarter ended on June 30, 2017. Further, as per code of conduct for prevention of Insider Trading adopted by the Company under SEBI [Prohibition of Insider Trading] Regulations, 2015, the Trading Window will remain closed from July 31, 2017 to August... Declaration regarding Audit Report
Zydus Wellness Ltd has informed BSE regarding Declaration regarding Audit Report for Financial Results for Period ended March 31, 2017 US regulatory nod for Zydus drug to treat dementia
We have received final approval from USFDA to market Memantine Hydrochloride tablets: Zydus Shareholding for the Period Ended June 30, 2017
Zydus Wellness Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2017. For more details, kindly Click here Status Of Complaints As On June 30, 2017
Please find attached herewith the complaint status as on June 30, 2017. Zydus begins Phase-II trials for its new anaemia drug Zyan1
Developed drug, an oral molecule, is the latest new chemical entity from the firm's pipeline USFDA nod for Zydus skin drug
Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA, has received final approval from the USFDA to market Nystatin Topical Powder USP, 100,000 units per gram. The drug will be...